• TAVR with Sapien 3 Valve Improves Quality of Life vs. SAVR in Low-Risk Patients, PARTNER 3 Substudy Shows

    SAN FRANCISCO – Patients at low risk for surgical mortality who underwent transcatheter aortic valve replacement (TAVR) with the balloon-expandable Sapien 3 valve demonstrated meaningful quality-of-life benefits compared with those who underwent surgical aortic valve replacement (SAVR), according to a substudy of the PARTNER 3 trial presented Sunday at Transcatheter Cardiovascular Therapeutics 2019.

    In presenting the results, Suzanne J. Baron, MD, MSc, of Saint Luke’s Mid-America Heart Institute, Kansas City, Missouri, noted that both PARTNER 3 and the Evolut low-risk trial, which compared low-risk patients who underwent TAVR with a self-expanding CoreValve, Evolut R or Evolut Pro valve (Medtronic), showed that transfemoral TAVR is safe and effective in these patients.

    Baron and colleagues conducted the quality-of-life prospective study alongside the PARTNER 3 trial to evaluate the health status of low-risk patients receiving the Sapien 3 valve. The primary endpoint was change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score over time, according to a manuscript simultaneously published in the Journal of the American College of Cardiology.

    At 1 month, TAVR was associated with health status than SAVR (mean difference in KCCQ score 16.0 points; p<0.001). At 6 and 12 months, health status remained better with TAVR, although the effect was reduced (mean difference in KCCQ score 2.6 points at 6 months and 1.8 points at 12 months; p<0.04 for both). The proportion of patients with excellent outcomes (alive with KCCQ ≥ 75 and no significant decline from baseline) was greater with TAVR than with SAVR at 6 months (TAVR 90.3% vs. SAVR 85.3%; p=0.03) and at 12 months, although the difference at this timepoint was not significant (TAVR 87.3% vs. 82.8%; p=0.07), Baron and colleagues reported.

    “Taken together with the clinical outcomes of the PARTNER 3 trial, these findings further support the use of TAVR in patients with severe aortic stenosis at low surgical risk,” Baron said during a press conference announcing the results.

    She added that longer-term follow-up is needed to determine whether the health-status benefit of TAVR lasts beyond 1 year in low-risk patients.

    The PARTNER 3 trial and quality-of-life substudy were funded by Edwards Lifesciences.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details